Last reviewed 2026-04-22 · How we verify

MenACWY-DT

Canadian Immunization Research Network · FDA-approved active Biologic

MenACWY-DT is a Conjugate vaccine Biologic drug developed by Canadian Immunization Research Network. It is currently FDA-approved for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. Also known as: Menactra.

MenACWY-DT is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide antigens to a diphtheria toxoid carrier protein. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

At a glance

Generic name	MenACWY-DT
Also known as	Menactra
Sponsor	Canadian Immunization Research Network
Drug class	Conjugate vaccine
Target	Neisseria meningitidis capsular polysaccharides (serogroups A, C, W, Y)
Modality	Biologic
Therapeutic area	Immunology / Infectious Disease
Phase	FDA-approved

Mechanism of action

The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y, each conjugated to diphtheria toxoid (DT) as a carrier protein. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in stronger and more durable antibody production compared to unconjugated polysaccharide vaccines. The induced antibodies provide protection against invasive meningococcal disease caused by these four serogroups.

Approved indications

Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y

Common side effects

Injection site pain
Injection site erythema
Injection site swelling
Myalgia
Headache
Fatigue
Fever

Key clinical trials

Adolescent MenACWY Booster Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MenACWY-DT CI brief — competitive landscape report
MenACWY-DT updates RSS · CI watch RSS
Canadian Immunization Research Network portfolio CI

Frequently asked questions about MenACWY-DT

What is MenACWY-DT?

MenACWY-DT is a Conjugate vaccine drug developed by Canadian Immunization Research Network, indicated for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

How does MenACWY-DT work?

What is MenACWY-DT used for?

MenACWY-DT is indicated for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

Who makes MenACWY-DT?

MenACWY-DT is developed and marketed by Canadian Immunization Research Network (see full Canadian Immunization Research Network pipeline at /company/canadian-immunization-research-network).

Is MenACWY-DT also known as anything else?

MenACWY-DT is also known as Menactra.

What drug class is MenACWY-DT in?

MenACWY-DT belongs to the Conjugate vaccine class. See all Conjugate vaccine drugs at /class/conjugate-vaccine.

What development phase is MenACWY-DT in?

MenACWY-DT is FDA-approved (marketed).

What are the side effects of MenACWY-DT?

Common side effects of MenACWY-DT include Injection site pain, Injection site erythema, Injection site swelling, Myalgia, Headache, Fatigue.

What does MenACWY-DT target?

MenACWY-DT targets Neisseria meningitidis capsular polysaccharides (serogroups A, C, W, Y) and is a Conjugate vaccine.

Drug class: All Conjugate vaccine drugs
Target: All drugs targeting Neisseria meningitidis capsular polysaccharides (serogroups A, C, W, Y)
Manufacturer: Canadian Immunization Research Network — full pipeline
Therapeutic area: All drugs in Immunology / Infectious Disease
Indication: Drugs for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Also known as: Menactra

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing